Revance Therapeutics (NASDAQ:RVNC) had its target price upped by Barclays from $35.00 to $38.00 in a research report sent to investors on Monday, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock.
Other research analysts have also recently issued reports about the company. Needham & Company LLC upped their price objective on Revance Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a research report on Thursday, October 15th. BidaskClub cut Revance Therapeutics from a hold rating to a sell rating in a research report on Thursday, October 1st. Mizuho began coverage on Revance Therapeutics in a research report on Tuesday, August 11th. They set a buy rating and a $32.00 price objective for the company. Zacks Investment Research cut Revance Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 12th. Finally, HC Wainwright upped their price objective on Revance Therapeutics from $27.00 to $33.00 and gave the stock a buy rating in a research report on Thursday, October 15th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $30.78.
RVNC opened at $26.01 on Monday. Revance Therapeutics has a 12 month low of $11.78 and a 12 month high of $34.62. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -6.16 and a beta of 1.77. The company has a debt-to-equity ratio of 0.68, a current ratio of 10.48 and a quick ratio of 10.46. The business has a fifty day moving average price of $27.06 and a 200 day moving average price of $23.78.
Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.16). The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $1.05 million. Revance Therapeutics had a negative return on equity of 88.96% and a negative net margin of 42,532.11%. On average, research analysts anticipate that Revance Therapeutics will post -4.26 earnings per share for the current year.
In other news, insider Aubrey Rankin sold 33,119 shares of the business’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $26.18, for a total value of $867,055.42. Following the completion of the sale, the insider now directly owns 67,871 shares of the company’s stock, valued at approximately $1,776,862.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.80% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the stock. Advisor Group Holdings Inc. acquired a new position in Revance Therapeutics in the 1st quarter valued at $37,000. Macquarie Group Ltd. purchased a new stake in shares of Revance Therapeutics in the second quarter valued at about $40,000. Meeder Asset Management Inc. increased its stake in shares of Revance Therapeutics by 66.3% during the first quarter. Meeder Asset Management Inc. now owns 2,699 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 1,076 shares during the period. Captrust Financial Advisors purchased a new position in Revance Therapeutics during the second quarter worth about $44,000. Finally, First Mercantile Trust Co. purchased a new position in Revance Therapeutics during the second quarter worth about $99,000. Hedge funds and other institutional investors own 76.75% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Read More: Channel Trading
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.